Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/COPD.S96070 http://scihub22266oqcxt.onion/10.2147/COPD.S96070 C4780202!4780202 !27042036     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27042036 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27042036 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Int+J+Chron+Obstruct+Pulmon+Dis 2016 ; 11 (ä): 439-44 Nephropedia Template TP {{tp|p=27042036 |t=2016. Striving for optimal bronchodilation: focus on olodaterol |pdf=|usr=}}{{27042036 }} gab.com Text Striving for optimal bronchodilation: focus on olodaterol JO: Int J Chron Obstruct Pulmon Dis http://www.kidney.de/pget.php?&tw=1&pmid=27042036 #FOAvip ?2-agonists were introduced in the 1940s as bronchodilators to be used in obstructive respiratory diseases. Long-acting ?2-agonists have been a mainstay of bronchodilating treatment for decades. Recently, agents extending their effect to 24 hours and thus allowing the once-daily administration were introduced, defined as very-long-acting ?2-agonists. Olodaterol is a new very-long-acting ?2-agonist that has been shown, in controlled trials, to improve lung function as well as clinical outcomes and quality of life. Most of these trials included patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD). Olodaterol has a rapid onset of action (comparable to formoterol) and provides bronchodilation over 24 hours. In controlled trials, olodaterol was shown to be as effective as formoterol twice daily, but significantly superior in terms of quality of life in patients with COPD. The safety profile of olodaterol was very good, with a rate of adverse events, including the cardiac events that are particularly important for ?2-agonists, comparable to placebo. Also, the efficiency of the Respimat(®) device concurs to the effectiveness of treatment. Twit Text FOAVip Striving for optimal bronchodilation: focus on olodaterol ????Int J Chron Obstruct Pulmon Dis http://www.kidney.de/pget.php?&tw=1&pmid=27042036 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27042036 #FOAvip English Wikipedia <ref>{{Cite pmid|27042036 }}</ref> Striving for optimal bronchodilation: focus on olodaterol #MMPMID27042036 Incorvaia C ; Montagni M ; Makri E ; Riario-Sforza GG ; Ridolo E Int J Chron Obstruct Pulmon Dis 2016[]; 11 (ä): 439-44 PMID27042036 show ga ?2-agonists were introduced in the 1940s as bronchodilators to be used in obstructive respiratory diseases. Long-acting ?2-agonists have been a mainstay of bronchodilating treatment for decades. Recently, agents extending their effect to 24 hours and thus allowing the once-daily administration were introduced, defined as very-long-acting ?2-agonists. Olodaterol is a new very-long-acting ?2-agonist that has been shown, in controlled trials, to improve lung function as well as clinical outcomes and quality of life. Most of these trials included patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD). Olodaterol has a rapid onset of action (comparable to formoterol) and provides bronchodilation over 24 hours. In controlled trials, olodaterol was shown to be as effective as formoterol twice daily, but significantly superior in terms of quality of life in patients with COPD. The safety profile of olodaterol was very good, with a rate of adverse events, including the cardiac events that are particularly important for ?2-agonists, comparable to placebo. Also, the efficiency of the Respimat(®) device concurs to the effectiveness of treatment. |Benzoxazines/*therapeutic use [MESH] |Bronchodilator Agents/*therapeutic use [MESH] |Clinical Trials as Topic [MESH] |Humans [MESH]Striving for optimal bronchodilation: focus on olodaterol (epmc).pdf DeepDyve Pubget Overpricing